keyword
MENU ▼
Read by QxMD icon Read
search

Adverse drug-drug interaction

keyword
https://www.readbyqxmd.com/read/29775399/dolutegravir-and-rilpivirine-for-the-maintenance-treatment-of-virologically-suppressed-hiv-1-infection
#1
Jose L Casado, Marta Monsalvo, Aurora M Rojo, María Fontecha, Miguel A Rodriguez-Sagrado
Triple combinations of antiretroviral (ART) drugs are the standard treatment for HIV infection, but the challenges include long-term side effects, high costs, and adherence. The recent advent of potent and well tolerated ART has renewed the interest for newer ART strategies. A dual regimen with the combination of dolutegravir (DTG) and rilpivirine (RPV), two well tolerated, metabolic-friendly, and potent drugs could offer additional benefits. Areas covered: A review of recent randomized trials and observational cohorts concerning the use of a dual therapy with DTG plus RPV as a switching strategy in patients with viral suppression...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29775322/prediction-of-human-cytochrome-p450-inhibition-using-a-multi-task-deep-autoencoder-neural-network
#2
Xiang Li, Youjun Xu, Luhua Lai, Jianfeng Pei
Adverse side effects of drug-drug interactions induced by human cytochrome P450 (CYP450) inhibition is an important consideration in drug discovery. It is highly desirable to develop computational models that can predict the inhibitive effect of a compound against a specific CYP450 isoform. In this study, we developed a multi-task model for concurrent inhibition prediction of five major CYP450 isoforms, namely 1A2, 2C9, 2C19, 2D6, and 3A4. The model was built by training multi-task autoencoder deep neural network (DNN) on a large dataset containing more than 13000 compounds, extracted from PubChem BioAssay Database...
May 18, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29767640/burden-of-exposure-to-potential-interactions-between-antiretroviral-and-non-antiretroviral-medications-in-a-population-of-hiv-positive-patients-aged-50-years-or-older
#3
Alice Ranzani, Letizia Oreni, Massimiliano Agrò, Lorena van den Bogaart, Laura Milazzo, Andrea Giacomelli, Dario Cattaneo, Cristina Gervasoni, Anna Lisa Ridolfo
BACKGROUND: As HIV-infected patients aged 50 years or older are at increased risk of comorbidities and multidrug treatments, we examined their exposure to the potential drug-drug interactions (PDDIs) of antiretroviral (ARV) and other medications. METHODS: This cross-sectional study involved the patients aged 50 years or older receiving ARV and non-ARV medications at our clinic. PDDIs were identified using the University of Liverpool HIV Drug Interaction Checker...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29766382/reduced-effectiveness-of-interruptive-drug-drug-interaction-alerts-after-conversion-to-a-commercial-electronic-health-record
#4
Adam Wright, Skye Aaron, Diane L Seger, Lipika Samal, Gordon D Schiff, David W Bates
BACKGROUND: Drug-drug interaction (DDI) alerts in electronic health records (EHRs) can help prevent adverse drug events, but such alerts are frequently overridden, raising concerns about their clinical usefulness and contribution to alert fatigue. OBJECTIVE: To study the effect of conversion to a commercial EHR on DDI alert and acceptance rates. DESIGN: Two before-and-after studies. PARTICIPANTS: 3277 clinicians who received a DDI alert in the outpatient setting...
May 15, 2018: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/29762878/risk-of-hypoglycemia-after-concomitant-use-of-antidiabetic-antihypertensive-and-antihyperlipidemic-medications-a-database-study
#5
Masahiko Gosho
Hypoglycemia is the most important complication of antidiabetic medications. Most patients with diabetes mellitus take multiple medications. In this study, we explored clinical drug-drug interactions that result in hypoglycemia by analyzing the Japanese Adverse Drug Event Report (JADER) database. The primary outcome was the report of hypoglycemia. The Norén and Gosho methods, which quantitatively measure the discrepancy between the observed and expected number of adverse events under the combination of 2 drugs, were used as the criteria for detecting drug-drug interactions...
May 15, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29762783/repurposing-the-anthelminthic-salicylanilide-oxyclozanide-against-susceptible-and-clinical-resistant-candida-albicans-strains
#6
Emilie Pic, Anaïs Burgain, Adnane Sellam
Current antifungal drugs suffer from limitations including toxicity, adverse interactions with other commonly prescribed drugs, and the emergence of resistant strains. Here, we repurposed the anthelmintic oxyclozanide as a potent antifungal agent against both sensitive and resistant clinical isolates of Candida albicans, as well as other human opportunistic fungi. Antifungal activity of oxyclozanide was enhanced when C. albicans grew in nonfermentable carbon sources. Our data support a mechanism of action where oxyclozanide uncoupled the mitochondrial electron transport from oxidative phosphorylation and perturbed the mitochondrial membrane potential...
May 14, 2018: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/29761349/intracochlear-administration-of-steroids-with-a-catheter-during-human-cochlear-implantation-a-safety-and-feasibility-study
#7
Nils K Prenzler, Rolf Salcher, Max Timm, Lutz Gaertner, Thomas Lenarz, Athanasia Warnecke
Suppression of foreign body reaction, improvement of electrode-nerve interaction, and preservation of residual hearing are essential research topics in cochlear implantation. Intracochlear pharmaco- or cell-based therapies can open new horizons in this field. Local drug delivery strategies are desirable as higher local concentrations of agents can be realized and side effects can be minimized compared to systemic administrations. When administered locally at accessible, basal parts of the cochlea, drugs reach apical regions later and in much lower concentrations due to poor diffusion patterns in cochlear fluids...
May 14, 2018: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/29759903/potential-adverse-drug-events-and-nephrotoxicity-related-to-prophylaxis-with-omeprazole-for-digestive-disorders-a-prospective-cohort-study
#8
Fabiana Rossi Varallo, Tales Rubens de Nadai, Alice Rosa Alves de Oliveira, Patricia de Carvalho Mastroianni
PURPOSE: The purpose of this study was to assess whether prophylaxis for digestive disorders with omeprazole is a risk factor for adverse drug events (ADEs) and kidney impairment. METHODS: This was a 9-month, prospective, double-blinded cohort study performed in a Brazilian public hospital. All inpatients 18 years or older admitted during the period of data collection were divided into 2 cohorts. The first group comprised 200 patients receiving prophylaxis for digestive disorders with omeprazole...
May 11, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29754836/misoprostol-for-small-bowel-ulcers-in-patients-with-obscure-bleeding-taking-aspirin-and-non-steroidal-anti-inflammatory-drugs-masters-a-randomised-double-blind-placebo-controlled-phase-3-trial
#9
Ali S Taha, Caroline McCloskey, Paula McSkimming, Alex McConnachie
BACKGROUND: The incidence of obscure gastrointestinal bleeding, which originates from the small bowel and is mainly associated with the use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), is rising. We assessed the efficacy and safety of misoprostol for the treatment of small bowel ulcers and erosions in patients taking low-dose aspirin or NSAIDs with obscure gastrointestinal bleeding. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients (aged ≥18 years) with small bowel ulcers who were taking low-dose aspirin, NSAIDs, or both for a minimum of 4 weeks, at University Hospital Crosshouse (Kilmarnock, UK)...
May 10, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29753941/an-integrated-computational-approach-of-molecular-dynamics-simulations-receptor-binding-studies-and-pharmacophore-mapping-analysis-in-search-of-potent-inhibitors-against-tuberculosis
#10
Shivangi Agarwal, Ekta Verma, Vivek Kumar, Namrita Lall, Samaresh Sau, Arun K Iyer, Sushil K Kashaw
Tuberculosis is an infectious chronic disease caused by obligate pathogen Mycobacterium tuberculosis that affects millions of people worldwide. Although many first and second line drugs are available for its treatment, but their irrational use has adversely lead to the emerging cases of multiple drug resistant and extensively drug-resistant tuberculosis. Therefore, there is an intense need to develop novel potent analogues for its treatment. This has prompted us to develop potent analogues against TB. The Mycobacterium tuberculosis genome provides us with number of validated targets to combat against TB...
May 3, 2018: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/29750016/spotlight-on-isavuconazole-in-the-treatment-of-invasive-aspergillosis-and-mucormycosis-design-development-and-place-in-therapy
#11
REVIEW
Jeffrey D Jenks, Helmut Jf Salzer, Juergen Prattes, Robert Krause, Dieter Buchheidt, Martin Hoenigl
In recent decades, important advances have been made in the diagnosis and treatment of invasive aspergillosis (IA) and mucormycosis. One of these advances has been the introduction of isavuconazole, a second-generation broad spectrum triazole with a favorable pharmacokinetic and safety profile and few drug-drug interactions. Phase III trials in patients with IA and mucormycosis demonstrated that isavuconazole has similar efficacy to voriconazole for the treatment of IA (SECURE trial) and liposomal amphotericin B for the treatment of mucormycosis (VITAL trial with subsequent case-control analysis) and a favorable safety profile with significantly fewer ocular, hepatobiliary, and skin and soft tissue adverse events compared to voriconazole...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29749262/comparison-of-the-effects-of-melatonin-and-oxazepam-on-anxiety-levels-and-sleep-quality-in-patients-with-st-segment-elevation-myocardial-infarction-following-primary-percutaneous-coronary-intervention-a-randomized-clinical-trial
#12
Padideh Ghaeli, Mohammad Solduzian, Shaghayegh Vejdani, Azita Hajhossein Talasaz
BACKGROUND: Anxiety and sleep disorders are prevalent problems in patients presenting with ST-segment-elevation myocardial infarction (STEMI). Usually, these problems are managed by benzodiazepines, which-albeit effective-could cause adverse effects and drug interaction. OBJECTIVE: This study was designed to compare the effects of melatonin and oxazepam in the management of anxiety and insomnia on patients following primary percutaneous coronary intervention (PCI) with a view to providing a safer alternative...
May 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29748012/a-phase-i-study-of-nintedanib-combined-with-cisplatin-gemcitabine-as-first-line-therapy-for-advanced-squamous-non-small-cell-lung-cancer-lume-lung-3
#13
Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembé, Rolf Kaiser, Siow Ming Lee
BACKGROUND: There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. MATERIALS AND METHODS: A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2 , Day 1), gemcitabine (1250 mg/m2 , Days 1 and 8) and nintedanib (Days 2-7, 9-21) were given for 4-6 cycles, followed by monotherapy until disease progression or adverse events (AEs)...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29747000/polysaccharides-based-multiparticulated-interpolyelectrolyte-complexes-for-controlled-benznidazole-release
#14
Mónica C García, Rubén H Manzo, Alvaro Jimenez-Kairuz
Polysaccharides-based delivery systems and interpolyelectrolyte complexes (IPECs) are interesting alternatives to control the release of drugs, thereby improving therapies. Benznidazole (BZ) is the selected drug for Chagas disease pharmacotherapy. However, its side effects limit its efficacy and safety. We developed novel multiparticulated BZ-loaded IPECs based on chitosan and alginic acid, and investigated their physicochemical and pharmacotechnical properties. IPECs were obtained using the casting solvent method, followed by wet granulation...
May 7, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29746724/efficacy-and-safety-of-elbasvir-grazoprevir-fixed-dose-in-the-management-of-polytreated-hcv-patients-evidence-from-real-life-clinical-practice
#15
Benedetto Caroleo, Lidia Colangelo, Maria Perticone, Giovambattista De Sarro, Luca Gallelli
Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. In this study, we evaluated both the clinical efficacy and safety of elbasvir-grazoprevir fixed-dose combination in HCV patients. We performed a prospective single-blind study on patients admitted to the Regional Center for HCV Treatment of the University of Catanzaro from March 1, 2017, to December 31, 2017, in patients >30 years old with a history of chronic HCV infection...
May 10, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29746101/systematic-approach-to-organizing-structural-alerts-for-reactive-metabolite-formation-from-potential-drugs
#16
Alf Claesson, Alexander Minidis
Reactive metabolites are widely accepted as playing a pivotal role in causing idiosyncratic adverse drug reactions (IDR). However, much is unknown about the biological mechanisms of IDR although the initiating event in most cases is an attachment of a reactive intermediate to macromolecules leading to immune mediated responses. Reactive metabolites are also involved in many mutagenesis/ carcinogenesis events by reacting with DNA. Drug designers thus have all reasons to make large efforts to avoid making test compounds having a liability to generate reactive metabolites...
May 10, 2018: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/29740921/hospitalization-and-morbidity-due-to-adverse-drug-reactions-in-elderly-patients-a-single-center-study
#17
Silvia Ognibene, Natale Vazzana, Claudio Giumelli, Luisa Savoldi, Luca Braglia, Giuseppe Chesi
BACKGROUND AND AIMS: Adverse drug reaction (ADRs) is a leading but underrecognized cause of illness particularly in frail subjects with multiple comorbidities. We aimed to investigate the frequency, patterns and outcomes of ADRs as a cause of hospitalization in elderly patients admitted to an internal medicine ward. METHODS: We performed a retrospective observational study including every patient aged over 65 years who was admitted to our Department during a 12-month period...
May 9, 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29740202/anti-integrin-therapy-for-inflammatory-bowel-disease
#18
REVIEW
Sung Chul Park, Yoon Tae Jeen
In inflammatory bowel disease (IBD), tumor necrosis factor plays an important role in mediating inflammation, but several other pathways are also involved in eliciting an inflammatory response. One such pathway is the invasion of the intestinal mucosa by leukocytes. Leukocytes within the systemic circulation move to sites of inflammation, and blocking this pathway could be an important treatment strategy for IBD. Anti-integrin therapy blocks the action of integrin on the surface of circulating immune cells and endothelial cell adhesion molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29739825/safety-ii-behavior-in-a-pediatric-intensive-care-unit
#19
Jenna Merandi, Kathryn Vannatta, J Terrance Davis, Richard E McClead, Richard Brilli, Thomas Bartman
: media-1vid110.1542/5763093009001PEDS-VA_2018-0018 Video Abstract BACKGROUND AND OBJECTIVE: Safety I error elimination concepts are focused on retrospectively investigating what went wrong and redesigning system processes and individual behaviors to prevent similar future occurrences. The Safety II approach recognizes complex systems and unpredictable circumstances, mandating flexibility and resilience within systems and among individuals to avoid errors. We hypothesized that in our high-complexity and high-risk PICU, Safety II concepts contribute to its remarkably low adverse drug event rate...
May 8, 2018: Pediatrics
https://www.readbyqxmd.com/read/29739235/a-new-perspective-on-the-nitrate-phosphodiesterase-type-5-inhibitor-interaction
#20
Robert A Kloner, Paul Goggin, Irwin Goldstein, Geoffrey Hackett, Michael G Kirby, Ian Osterloh, John D Parker, Richard Sadovsky
BACKGROUND: Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together with nitrates, synergistic effects that enhance hypotensive effects may occur. Phosphodiesterase type 5 inhibitors are therefore contraindicated in patients taking organic nitrates. METHODS AND RESULTS: A literature review was performed to provide a historical overview of different phosphodiesterase type 5 inhibitors and nitrates and their interaction...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
keyword
keyword
112626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"